Lisa Cook sues Trump over firing attempt, emergency hearing set
Igm Biosciences (NASDAQ:IGMS) Chief Financial Officer Misbah Tahir sold 8,741 shares of common stock on July 23, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as the company’s stock has declined nearly 89% over the past year, with market capitalization now at $76.44 million. According to InvestingPro data, the company maintains a strong liquidity position with cash exceeding debt, though its overall financial health score remains weak. The shares were sold at a weighted average price of $1.2728, for a total transaction value of $11,125.
The sales were executed in multiple trades with prices ranging from $1.27 to $1.275. The shares were sold to cover tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Tahir directly owns 170,061 shares of Igm Biosciences. With the company’s next earnings report due in 16 days, InvestingPro subscribers can access 10+ additional investment tips and comprehensive analysis through the Pro Research Report.
In other recent news, IGM Biosciences has announced a definitive merger agreement to be acquired by Concentra Biosciences. Under the terms of the deal, Concentra will acquire IGM Biosciences for $1.247 in cash per share, along with a non-tradeable contingent value right (CVR). The CVR allows shareholders to receive 100% of IGM’s closing net cash exceeding $82 million and 80% of any net proceeds from the sale of specific product candidates and intellectual property within a year after the transaction closes. Additionally, IGM Biosciences has ended a significant collaboration and license agreement with Genzyme Corporation, a Sanofi (NASDAQ:SNY) entity. This agreement, which began on March 28, 2022, focused on developing IgM antibodies for diseases such as cancer and immunological disorders. The termination notice was received by IGM Biosciences on May 5, 2025, and will take effect 30 days from the notice date. Both companies have mutually decided that continuing the agreement is not in their best interests. These developments mark a significant period of change for IGM Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.